Psychopharmacology
November 8, 2017
R. L. Carhart-Harris, Mark Bolstridge, C. M. J. Day et al.
978 citations
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major...
Journal watch
November 3, 2017
In 1970, the FDA categorized psilocybin as a Schedule 1 drug, largely because of its recreational uses, which include inducing spirituality and
Psychopharmacology
October 30, 2017
J. B. Stroud, Tom P. Freeman, Robert Leech et al.
102 citations
RATIONALE: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. OBJECTIVES: The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in treatment-resistant depression (TRD), alters patients' emotional processing biases. METHODS: Seventeen patients with...
Personality and Individual Differences
October 15, 2017
Frederick S. Barrett, Matthew W Johnson, Roland R. Griffiths
98 citations
Classic hallucinogens (e.g. psilocybin and LSD) have substantial effects on perception, cognition, and emotion that can often be psychologically challenging, however we know very little regarding the source of significant individual variability that has been observed in the frequency and intensity of challenging experiences (i.e. "bad trips") with psychedelics. Previous clinical and...
Scientific Reports
October 13, 2017
Robin Carhart-Harris, Leor Roseman, Mark Bolstridge et al.
590 citations
Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for...
Journal of Psychopharmacology
October 11, 2017
Roland R. Griffiths, Matthew W. Johnson, William A. Richards et al.
528 citations
Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very low-dose (1 mg/70 kg on sessions 1 and 2)...
Journal of Natural Products
September 20, 2017
Claudius Lenz, Jonas Wick, Dirk Hoffmeister
62 citations
We report the identification of ω-N-methyl-4-hydroxytryptamine (norpsilocin, 1) from the carpophores of the hallucinogenic mushroom Psilocybe cubensis. The structure was elucidated by 1D and 2D NMR spectroscopy and high-resolution mass spectrometry. Norpsilocin has not previously been reported as a natural product. It likely represents the actual psychotropic agent liberated from its...
Angewandte Chemie
August 1, 2017
Janis Fricke, Felix Blei, Dirk Hoffmeister
26 citations
Abstract Psilocybin ist der psychotrope, vom Tryptamin abgeleitete Naturstoff der Psilocybe‐Fruchtkörper, der so genannten “Zauberpilze”. Obwohl dessen Struktur seit 60 Jahren bekannt ist, blieb die enzymatische Grundlage ihrer Biosynthese ungeklärt. Wir charakterisierten vier Psilocybin‐Biosyntheseenzyme, nämlich i) PsiD, welches zu einer neuen Klasse pilzlicher l ‐Tryptophan‐Decarboxylasen...
Angewandte Chemie International Edition
August 1, 2017
Janis Fricke, Felix Blei, Dirk Hoffmeister
210 citations
Abstract Psilocybin is the psychotropic tryptamine‐derived natural product of Psilocybe carpophores, the so‐called “magic mushrooms”. Although its structure has been known for 60 years, the enzymatic basis of its biosynthesis has remained obscure. We characterized four psilocybin biosynthesis enzymes, namely i) PsiD, which represents a new class of fungal l ‐tryptophan decarboxylases, ii) PsiK,...
Neuroimage
July 12, 2017
Candace R. Lewis, Katrin H. Preller, Rainer Kraehenmann et al.
105 citations
Psilocybin, the active compound in psychedelic mushrooms, is an agonist of various serotonin receptors. Seminal psilocybin positron emission tomography (PET) research suggested regional increases in glucose metabolism in frontal cortex (hyperfrontality). However, a recent arterial spin labeling (ASL) study suggests psilocybin may lead to hypo-perfusion in various brain regions. In this...